Shares of uniQure burst higher today. Here's why.
These three healthcare stocks could offer the best blend of sales and dividend growth in the sector.
Three contributors weigh in.
Bristol-Myers Squibb is pursuing FDA approval that would allow its daclatasvir to be used alongside Sovaldi in genotype 3 patients.
Pfizer and Bristol-Myers Squibb are two top dividend stocks. Which one offers the better investing opportunity going forward?
We'd like to think that the billions of dollars being spent annually on cancer drug development are making a sizable impact on the lives of cancer patients. But, that may not be the case, according to this latest study.
Our experts weigh in.
Motley Fool experts discuss whether Bristol-Myers Squibb's Opdivo or Merck & Co.'s Keytruda will be the bigger commercial success.
Is this meaningful or just another movement?
Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.